I don’t know that many people argue Vascepa can get to sale level anywhere close to top selling statin of the past. Few did argue with me conceded when we tried to put that vague point to revenue estimates. It seems pointless to argue on that front.
With generally broad label like that, it would be relatively easy to get to $3B or greater level which is more or less analysts’ current estimates especially in a big biopharma’s hand. This isn’t HCV outer years revenue estimate by analysts in the beginning that missed by marathons because they couldn’t see the inevitable price erosion some others had the foresight to see - some still blame ABBV rather than fundamentals. This is pretty simple and straightforward IMO.
Market Data 
Markets 
AI
